Innocoll, Inc. Granted Two Patents for Wound-Healing Products

ASTON, Pa. -- Innocoll, Inc. announced that its wholly owned subsidiary, Syntacoll AG, has been granted two important patents.  U.S. Patent No. 6,855,860 entitled Composite Dressings for Treatment of Wounds was issued by the United States Patent and Trademark Office and patent No.  1263485 entitled Multilayer Collagen Matrix for Tissue Reconstruction by the European Patent Office.

The U.S. patent covers a product comprised of a novel collagen-based composite material designed for the treatment of deep wounds, or wounds that penetrate the middle and deepest layers of skin, or dermis.  These deep wounds occur in second- or third-degree burns and in a variety of acute and/or chronic skin disorders, such as leg ulcers and pressure ulcers.

The EU patent covers the use and manufacture of multi-layer collagen-based matrices for surgical applications including tissue and organ reconstruction.  The collagen matrices are capable of promoting formation of granulation tissue, angiogenesis, and vascularization, and may also be used for the targeted delivery of bioactive agents to a specific tissue or organ.

In addition to its focus on the development and commercialization of post-surgical implants to treat pain and infection, Innocoll is also developing a series of products for wound management using its proprietary, commercialized collagen-based delivery technology, CollaRx. CollaRx products are approved in 45 countries in North America, Europe, South America, Asia and Africa.  Innocolls lead product, COLLATAMP® G, is a biodegradable implant that locally delivers high concentration of the broad spectrum antibiotic, gentamicin, for the treatment and prevention of post-surgical acquired infection.

Dr. Michael Myers, president and CEO, commented, The issuing of these patents is indicative of two of Innocolls strategic goals:  broadening our intellectual property base and developing improved differentiated products that effectively and safely deliver high local concentrations of active medicines with minimal systemic absorption.

Source: Innocoll, Inc.